Table 4.
Observed Probability of Events among patient groups
| Events | Patient Group 1 (N=64) | Patient Group 2 (N=30) |
|---|---|---|
| dnDSA, no. (%)1 | (6) 10.0% | (4) 13.8% |
| ACR 2+, no. (%) | (3) 4.7% | |
| AMR 1+, no. (%) | (4) 6.3% | (2) 6.7% |
| Death, no. (%)1 | (4) 6.3% | |
| CAV by Angio 1+, no. (%)1 | (39) 73.6% | (15) 60.0% |
| CAV by IVUS 1+, no. (%)1 | (33) 89.2% | (13) 92.9% |
| Combined Endpoint, no. (%) | (51) 79.7% | (20) 66.7% |
Notes:
1
Total sample size less than 94;
dnDSA indicates Donor Specific Antibodies, CAV Cardiac Allograft Vasculopathy, Angio, angiogram; ivus, intravascular ultrasound; combined end point is defined as time to either death, re-transplantation, ACR, 2+, AMR, 1+, ISHLT CAV 1+ by angiogram, or ISHLT CAV 1+ by intravascular ultrasound.